Omega-3 Deficiency and Cardiac Events
The American Heart Association released a scientific statement in 2002 acknowledging that the dietary consumption of Omega-3 polyunsaturated fatty acids reduces the incidence of cardiovascular disease. – Kris-Etherton 2002; Circulation
Blood levels of long-chain Omega-3 polyunsaturated fatty acids have been shown to be strongly associated with a reduced risk of sudden death in apparently healthy males. – Albert, 2007; New England Journal of Medicine
Prospective randomized intervention studies have shown that dietary supplementation with two Omega-3 polyunsaturated fatty acids, namely EPA and DHA, significantly reduces the risk of death, recurrent nonfatal myocardial infarction or stroke in patients who have already suffered a myocardial infarction.
Randomized placebo-controlled studies have also shown that dietary supplementation with either EPA or DHA alone significantly increased blood levels of Omega-3 polyunsaturated fatty acids and significantly reduced blood triglyceride levels, both in mildly hyperlipidemic males and apparently healthy males – Mori, 2000 & Grimsgard 1997; American Journal of Clinical Nutrition
Dietary supplementation with EPA and DHA is also generally well-tolerated, with few side effects.
VASCAZENTM is intended for the dietary management of cardiovascular disease, in patients deficient in Omega-3 and raises EPA and DHA to levels associated with cardioprotection, and prevention of sudden cardiac death.